ApprovalTrail

Drug · DIN 02532468

SUNLENCA

Yes: authorized and sold in Canada

Authorized, and the company reports that it sells it in Canada.

Status Marketed since March 15, 2023; first marketed March 15, 2023.
Drug Identification Number (DIN)
02532468
Company (DIN owner)
Gilead Sciences Canada IncMississauga, Ontario, Canada
Schedule
Prescription
Dosage form
Tablet
Route
Oral
Therapeutic class (ATC)
Lenacapavir J05AX31
Class
Human
Record last updated
September 10, 2026

Active ingredients

As listed in the Drug Product Database.

IngredientStrengthPer
LENACAPAVIR (LENACAPAVIR SODIUM)300 MG

Notices of Compliance

Health Canada approvals that name this DIN.

Other DINs named SUNLENCA